UCL Discovery Stage
UCL home » Library Services » Electronic resources » UCL Discovery Stage

Glucocorticoid treatment in patients with newly diagnosed immune thrombocytopenia switches CD14(++)CD16(+) intermediate monocytes from a pro-inflammatory to an anti-inflammatory phenotype

Williams, EL; Stimpson, ML; Lait, PJP; Schewitz-Bowers, LP; Jones, LV; Dhanda, AD; Lee, RWJ; (2020) Glucocorticoid treatment in patients with newly diagnosed immune thrombocytopenia switches CD14(++)CD16(+) intermediate monocytes from a pro-inflammatory to an anti-inflammatory phenotype. British Journal of Haematology 10.1111/bjh.17205. (In press). Green open access

[thumbnail of bjh.17205.pdf]
Preview
Text
bjh.17205.pdf - Published Version

Download (3MB) | Preview

Abstract

Immune thrombocytopenia (ITP) is thought to result from an aberrant adaptive autoimmune response, involving autoantibodies, B and T lymphocytes, directed at platelets and megakaryocytes. Previous reports have demonstrated skewed CD4+ T-helper subset distribution and enhanced production of pro-inflammatory cytokines such as interleukin 17A and interferon gamma. The role of monocytes (MCs) in ITP is less widely described, but innate immune cells have a role in shaping CD4+ T-cell phenotypes. Glucocorticoids (GCs) are commonly used for first-line ITP treatment and modulate a broad range of immune cells including T cells and MCs. Using multiparameter flow cytometry analysis, we demonstrate the expansion of intermediate MCs (CD14++CD16+ ) in untreated patients with newly diagnosed ITP, with these cells displaying a pro-inflammatory phenotype, characterised by enhanced expression of CD64 and CD80. After 2 weeks of prednisolone treatment (1 mg/kg daily), the proportion of intermediate MCs reduced, with enhanced expression of the anti-inflammatory markers CD206 and CD163. Healthy control MCs were distinctly different than MCs from patients with ITP before and after GC treatment. Furthermore, the GC-induced phenotype was not observed in patients with chronic ITP receiving thrombopoietin receptor agonists. These data suggest a role of MCs in ITP pathogenesis and clinical response to GC therapy.

Type: Article
Title: Glucocorticoid treatment in patients with newly diagnosed immune thrombocytopenia switches CD14(++)CD16(+) intermediate monocytes from a pro-inflammatory to an anti-inflammatory phenotype
Open access status: An open access version is available from UCL Discovery
DOI: 10.1111/bjh.17205
Publisher version: https://doi.org/10.1111/bjh.17205
Language: English
Additional information: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0/
Keywords: autoimmunity, glucocorticoids, steroids, immune thrombocytopenia, monocyte subsets.
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Institute of Ophthalmology
URI: https://discovery-pp.ucl.ac.uk/id/eprint/10118443
Downloads since deposit
984Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item